Clinical Trials Logo

Recurrent Multiple Myeloma clinical trials

View clinical trials related to Recurrent Multiple Myeloma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03770260 Completed - Clinical trials for Refractory Multiple Myeloma

Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment

Start date: February 10, 2020
Phase: Phase 1
Study type: Interventional

This phase Ib trial studies side effects and best dose of pevonedistat when given together with ixazomib in treating patients with multiple myeloma that has come back or does not respond to treatment. Pevonedistat and ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02101944 Completed - Anemia Clinical Trials

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Start date: December 9, 2014
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of wild-type reovirus when combined with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back following treatment (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as dexamethasone and carfilzomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. A virus called wild-type reovirus may be able to kill cancer cells without damaging normal cells and seems to work best when given with chemotherapy. Giving wild-type reovirus with chemotherapy may be a more effective treatment than chemotherapy alone.